Regeneron Pharmaceuticals has paused critically ill COVID-19 patients’ enrollment

Regeneron Pharmaceuticals has paused critically ill COVID-19 patients’ enrollment with its trial studying the antibody cocktail treatment, which was fond of President Trump earlier this month.